Clinical trials: HCM
Hypertrophic Cardiomyopathy
Prognostic Value of Angio-IMR in Hypertrophic Cardiomyopathy Patients
Coronary microvascular dysfunction (CMD) is among pathophysiological states of significance in hypertrophic cardiomyopathy (HCM).
- Trial name
- NCT06434415
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Heart Failure
The Effects of Dobutamine on Postoperative Cardiac Function in Aortic Valve Replacement
The use of dobutamine in postoperative hemodynamic treatment is widespread despite seemingly intact contraction of the heart. This study aims to elucidate the efficacy of low-dose dobutamine infusion in patients in the…
- Trial name
- NCT01375335
- Testing
- Dobutamine
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- University of Aarhus
Hypertrophic Cardiomyopathy (HCM)
Role of Cardiovascular Imaging in the Early Diagnosis of Hypertrophic Cardiomyopathy in Women
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disorder worldwide with a prevalence of 1:500 in the general population.
- Trial name
- IMAGE-HCM (NCT06882668)
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Hypertrophic Cardiomyopathy
High Intensity Exercise for Increasing Fitness in Patients With Hypertrophic Cardiomyopathy
Although current clinical guidelines stipulate that patients with hypertrophic cardiomyopathy should not partake in high intensity exercise (HIE) or competitive sport due to safety concerns, there is no clear evidence to support…
- Trial name
- NCT03335332
- Testing
- High intensity exercise, Moderate intensity exercise
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Texas Southwestern Medical Center
Hypertrophic Obstructive Cardiomyopathy, Thoracic Aortic Dilatation
A Cardiac Disease Quality of Life Study
A prospective, longitudinal, non-comparator, non-randomized observational cohort study to assess the quality of life in adult patients affected by hypertrophic cardiomyopathy and thoracic aortic dilatations who are not amenable…
- Conditions
- Hypertrophic Obstructive Cardiomyopathy, Thoracic Aortic Dilatation, Heart Disease Caused by Ionising Radiation, Quality of Life
- Trial name
- UPLIFT (NCT04080492)
- Testing
- QOL Survey
- Where
- United States
- Volunteers
- 380 people
- Sponsor
- The Cleveland Clinic
Choreatic Disorder
Heart and Skeletal Muscle Problems in Neuroacanthocytosis
The purpose of this study is to learn about heart and skeletal muscle problems related to neuroacanthocytosis (also called Mcleod's syndrome and Levine-Critchley disease).
- Trial name
- NCT00007228
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Cardiomyopathy (HCM)
Multicentre Hypertrophic Cardiomyopathy Registry
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition, affecting approximately 1 in 500 people. It causes the heart muscle to thicken, which can lead to blockages in blood flow (left ventricular outflow…
- Trial name
- NCT07381894
- Where
- United Kingdom
- Volunteers
- 2,500 people
- Sponsor
- University of Manchester
Hypertrophic Cardiomyopathy (HCM)
One-stop Evaluation of Hypertrophic Cardiomyopathy in Cardiac Magnetic Resonance
This is a multi-center, observational study aiming to establish a precision diagnosis scheme and multi-dimensional risk prediction models for Hypertrophic Cardiomyopathy (HCM). The study plans to enroll 10000 adult HCM patients.
- Trial name
- NCT07336290
- Volunteers
- 10,000 people
- Sponsor
- Minjie Lu
Hypertrophic Cardiomyopathy
A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy
The purpose of this research study is to understand more about various heart rhythms (electrical problems) in persons with hypertrophic cardiomyopathy with and without sleep apnea.
- Trial name
- NCT04112290
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Mayo Clinic
Hypertrophic Cardiomyopathy
CHANCE - Candesartan in Hypertrophic Cardiomyopathy
The primary hypothesis of the study is that treatment with AT1-R antagonist in patients with nonobstructive form of HCM will be first save, second will cause regression of myocardial hypertrophy.
- Trial name
- NCT00430833
- Testing
- candesartan
- Where
- Czechia
- Sponsor
- Charles University, Czech Republic
Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitors
Radiomics Analysis of CMR Imaging for Arrhythmic Risk Prediction in Hypertrophic Cardiomyopathy, With Longitudinal Risk Reassessment After Mavacamten Therapy in Obstructive Patients
Hypertrophic cardiomyopathy (HCM) is one of the leading causes of sudden cardiac death (SCD), particularly in young and middle-aged individuals.
- Trial name
- RADIOMICS-OHCM (NCT07695272)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Centro Cardiologico Monzino
Hypertrophic Obstructive Cardiomyopathy
The Effect of TASH in Patients With HOCM
To examine patients with hypertrophic obstructive cardiomyopathy (HOCM) before and after septal alcohol ablation, to investigate the effect of the treatment in regards to changes in myocardial function, perfusion, invasive…
- Trial name
- Post-TASH (NCT04066777)
- Testing
- alcohol septal ablation
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Steen Hvitfeldt Poulsen
Rare Diseases, Fabry Disease
Evaluation of HEArt invoLvement in Patients With FABRY Disease
This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.
- Conditions
- Rare Diseases, Fabry Disease, Fabry Disease, Cardiac Variant, Hypertrophic Cardiomyopathy
- Trial name
- HEAL-FABRY (NCT03362164)
- Where
- Germany
- Volunteers
- 650 people
- Sponsor
- Wuerzburg University Hospital
Hypertrophic Cardiomyopathies, Athlete Heart
Role of CMR-FT in Assessment of HCM and Athlete's Heart.
Using cardiac MRI feature tracking to asses myocardial motion differences in athlete's heart and discovered hypertrophic cardiomyopathy patients to increase diagnostic accuracy of hypertrophic cardiomyopathy.
- Trial name
- NCT06859827
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sohag University
Hypertrophic Cardiomyopathy
The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.
Hypertrophic obstructive cardiomyopathy (HOCM) patients often develop disabling symptoms of heart failure. Current treatment strategies are predicated on the empirical use of long-standing drugs, such as beta-adrenergics…
- Trial name
- TEMPO (NCT03532802)
- Testing
- Metoprolol Succinate
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Steen Hvitfeldt Poulsen
HCM - Hypertrophic Cardiomyopathy, Anderson Fabry Disease
Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes
This observational study aims to evaluate myocardial perfusion abnormalities using quantitative and qualitative cardiac magnetic resonance (CMR) perfusion imaging in patients with hypertrophic cardiomyopathy (HCM) phenotypes…
- Conditions
- HCM - Hypertrophic Cardiomyopathy, Anderson Fabry Disease, Cardiac Magnetic Resonance Imaging, Amyloid Cardiomyopathy
- Trial name
- MyoPerf-HCM (NCT07382128)
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Obesity, Hypertrophic Cardiomyopathy
Association of Obesity and Cardiovascular Outcomes in Hypertrophic Cardiomyopathy
In this study, the investigators evaluated the association between various measures of adiposity [BMI and waist circumference (WC)] and clinical outcomes in Asian patients with hypertrophic cardiomyopathy, using a nationwide…
- Conditions
- Obesity, Hypertrophic Cardiomyopathy, Cardiovascular Morbidity
- Trial name
- Paradox (NCT05645939)
- Testing
- Diasgnosis of hypertrophic cardiomyopathy
- Where
- South Korea
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- Ajou University School of Medicine
Hypertrophic Cardiomyopathy
Family Studies of Inherited Heart Disease
Hypertrophic cardiomyopathy (HCM) is a genetically inherited heart disease. It causes thickening of heart muscle, especially the chamber responsible for pumping blood out of the heart, the left ventricle.
- Trial name
- NCT00001225
- Where
- United States
- Volunteers
- 5,880 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Non-obstructive Hypertrophic Cardiomyopathy
A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy
This study mainly evaluated the safety and tolerability of HRS-1893 in subjects with non-obstructive hypertrophic cardiomyopathy, and the efficacy and plasma concentrations of different dosing regimens in subjects with…
- Trial name
- NCT06816251
- Testing
- HRS-1893
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Atrial Fibrillation, Hypertrophic Cardiomyopathy
HCM-AF Ablation With ACUTUS
BACKGROUND About 1/4 of patients with hypertrophic cardiomyopathy (HCM) seem to develop atrial fibrillation (AF) over their life-span.
- Trial name
- NCT04090437
- Testing
- Catheter ablation procedure
- Volunteers
- 20 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust